vs
Side-by-side financial comparison of Bio-Techne (TECH) and WOLVERINE WORLD WIDE INC (WWW). Click either name above to swap in a different company.
WOLVERINE WORLD WIDE INC is the larger business by last-quarter revenue ($517.5M vs $311.4M, roughly 1.7× Bio-Techne). Bio-Techne runs the higher net margin — 16.4% vs 6.1%, a 10.2% gap on every dollar of revenue. On growth, WOLVERINE WORLD WIDE INC posted the faster year-over-year revenue change (25.5% vs -1.5%). Over the past eight quarters, WOLVERINE WORLD WIDE INC's revenue compounded faster (14.5% CAGR vs 1.3%).
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
Wolverine World Wide is a global designer, manufacturer and marketer of branded footwear, apparel and accessories. It owns popular brands including Merrell, Sperry, Saucony and Hush Puppies, serving outdoor, casual, workwear and athletic segments via e-commerce, retail stores and global wholesale networks.
TECH vs WWW — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $311.4M | $517.5M |
| Net Profit | $51.0M | $31.8M |
| Gross Margin | 66.9% | 47.3% |
| Operating Margin | 24.2% | 9.7% |
| Net Margin | 16.4% | 6.1% |
| Revenue YoY | -1.5% | 25.5% |
| Net Profit YoY | 126.0% | 162.8% |
| EPS (diluted) | $0.32 | $0.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $311.4M | $517.5M | ||
| Q4 25 | $295.9M | — | ||
| Q3 25 | — | $470.3M | ||
| Q2 25 | $317.0M | $474.2M | ||
| Q1 25 | $316.2M | $412.3M | ||
| Q4 24 | $297.0M | $494.7M | ||
| Q3 24 | $289.5M | $440.2M | ||
| Q2 24 | $306.1M | $425.2M |
| Q1 26 | $51.0M | $31.8M | ||
| Q4 25 | $38.0M | — | ||
| Q3 25 | — | $25.1M | ||
| Q2 25 | $-17.7M | $26.8M | ||
| Q1 25 | $22.6M | $12.1M | ||
| Q4 24 | $34.9M | $23.1M | ||
| Q3 24 | $33.6M | $23.2M | ||
| Q2 24 | $40.6M | $13.8M |
| Q1 26 | 66.9% | 47.3% | ||
| Q4 25 | 64.6% | — | ||
| Q3 25 | — | 47.5% | ||
| Q2 25 | 62.7% | 47.2% | ||
| Q1 25 | 67.9% | 47.2% | ||
| Q4 24 | 65.3% | 43.4% | ||
| Q3 24 | 63.2% | 45.1% | ||
| Q2 24 | 66.4% | 43.1% |
| Q1 26 | 24.2% | 9.7% | ||
| Q4 25 | 18.4% | — | ||
| Q3 25 | — | 8.4% | ||
| Q2 25 | -7.5% | 8.6% | ||
| Q1 25 | 12.2% | 4.8% | ||
| Q4 24 | 16.0% | 7.4% | ||
| Q3 24 | 13.8% | 7.9% | ||
| Q2 24 | 15.0% | 6.8% |
| Q1 26 | 16.4% | 6.1% | ||
| Q4 25 | 12.8% | — | ||
| Q3 25 | — | 5.3% | ||
| Q2 25 | -5.6% | 5.7% | ||
| Q1 25 | 7.1% | 2.9% | ||
| Q4 24 | 11.7% | 4.7% | ||
| Q3 24 | 11.6% | 5.3% | ||
| Q2 24 | 13.3% | 3.2% |
| Q1 26 | $0.32 | $0.37 | ||
| Q4 25 | $0.24 | — | ||
| Q3 25 | — | $0.30 | ||
| Q2 25 | $-0.11 | $0.32 | ||
| Q1 25 | $0.14 | $0.15 | ||
| Q4 24 | $0.22 | $0.29 | ||
| Q3 24 | $0.21 | $0.28 | ||
| Q2 24 | $0.26 | $0.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $209.8M | — |
| Total DebtLower is stronger | — | $621.7M |
| Stockholders' EquityBook value | $2.1B | $408.0M |
| Total Assets | $2.6B | $1.7B |
| Debt / EquityLower = less leverage | — | 1.52× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $209.8M | — | ||
| Q4 25 | $172.9M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $162.2M | — | ||
| Q1 25 | $140.7M | — | ||
| Q4 24 | $177.5M | — | ||
| Q3 24 | $187.5M | — | ||
| Q2 24 | $152.9M | — |
| Q1 26 | — | $621.7M | ||
| Q4 25 | $260.0M | — | ||
| Q3 25 | — | $676.4M | ||
| Q2 25 | $346.0M | $708.5M | ||
| Q1 25 | $330.0M | $710.8M | ||
| Q4 24 | $300.0M | $648.0M | ||
| Q3 24 | $300.0M | $702.8M | ||
| Q2 24 | $319.0M | $814.7M |
| Q1 26 | $2.1B | $408.0M | ||
| Q4 25 | $2.0B | — | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | $1.9B | $344.0M | ||
| Q1 25 | $2.0B | $310.6M | ||
| Q4 24 | $2.1B | $312.9M | ||
| Q3 24 | $2.1B | $295.2M | ||
| Q2 24 | $2.1B | $262.1M |
| Q1 26 | $2.6B | $1.7B | ||
| Q4 25 | $2.5B | — | ||
| Q3 25 | — | $1.7B | ||
| Q2 25 | $2.6B | $1.8B | ||
| Q1 25 | $2.6B | $1.7B | ||
| Q4 24 | $2.7B | $1.7B | ||
| Q3 24 | $2.7B | $1.8B | ||
| Q2 24 | $2.7B | $1.8B |
| Q1 26 | — | 1.52× | ||
| Q4 25 | 0.13× | — | ||
| Q3 25 | — | 1.80× | ||
| Q2 25 | 0.18× | 2.06× | ||
| Q1 25 | 0.16× | 2.29× | ||
| Q4 24 | 0.14× | 2.07× | ||
| Q3 24 | 0.14× | 2.38× | ||
| Q2 24 | 0.15× | 3.11× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $146.2M |
| Free Cash FlowOCF − Capex | — | $145.6M |
| FCF MarginFCF / Revenue | — | 28.1% |
| Capex IntensityCapex / Revenue | — | 0.1% |
| Cash ConversionOCF / Net Profit | — | 4.60× |
| TTM Free Cash FlowTrailing 4 quarters | — | $125.5M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $146.2M | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $33.0M | ||
| Q2 25 | $98.2M | $44.6M | ||
| Q1 25 | $41.1M | $-83.8M | ||
| Q4 24 | $84.3M | $82.4M | ||
| Q3 24 | $63.9M | $108.2M | ||
| Q2 24 | $75.5M | $26.7M |
| Q1 26 | — | $145.6M | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $30.1M | ||
| Q2 25 | $93.3M | $41.2M | ||
| Q1 25 | $31.0M | $-91.4M | ||
| Q4 24 | $77.5M | $74.4M | ||
| Q3 24 | $54.7M | $104.1M | ||
| Q2 24 | $57.5M | $23.7M |
| Q1 26 | — | 28.1% | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 6.4% | ||
| Q2 25 | 29.4% | 8.7% | ||
| Q1 25 | 9.8% | -22.2% | ||
| Q4 24 | 26.1% | 15.0% | ||
| Q3 24 | 18.9% | 23.6% | ||
| Q2 24 | 18.8% | 5.6% |
| Q1 26 | — | 0.1% | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 0.6% | ||
| Q2 25 | 1.5% | 0.7% | ||
| Q1 25 | 3.2% | 1.8% | ||
| Q4 24 | 2.3% | 1.6% | ||
| Q3 24 | 3.2% | 0.9% | ||
| Q2 24 | 5.9% | 0.7% |
| Q1 26 | — | 4.60× | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 1.31× | ||
| Q2 25 | — | 1.66× | ||
| Q1 25 | 1.82× | -6.93× | ||
| Q4 24 | 2.42× | 3.57× | ||
| Q3 24 | 1.90× | 4.66× | ||
| Q2 24 | 1.86× | 1.93× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
TECH
| Protein Sciences segment revenue | $226.2M | 73% |
| Diagnostics and Spatial Biology segment revenue | $85.6M | 27% |
| Other revenue (1) | $5.4M | 2% |
WWW
| Sales Channel Through Intermediary | $230.2M | 44% |
| Sales Channel Directly To Consumer | $142.6M | 28% |
| Work Group | $134.0M | 26% |
| Other | $10.7M | 2% |
